CHARACTERIZATION OF MICROBIAL FLORA IN PATIENTS SUSPECTED OF HAVING UROGENITAL TUBERCULOSIS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction In the structure of tuberculosis morbidity, urogenital tuberculosis (UGT) ranks second or third only to pulmonary tuberculosis. Every fourth patient has the stage of cavern formation at first presentation. Seventy five percent of nephrotuberculosis cases co-occur with nonspecific pyelonephritis, which excludes «sterile pyuria». We aimed to determine the microbial spectrum of urine and gonadal appendages in patients with suspected UGT and to investigate the susceptibility of the isolated microorganisms to the main antibacterial drugs. Material and methods The study investigated the spectrum of pathogenic microflora isolated from patients admitted to the urogenital clinic of the TB Research Institute from January 1, 2012 to September 30, 2016 to rule out UGT. Microorganism species were identified by time-of-flight mass spectrometry using the microbiological analyzer Phoenix 100 (Becton Dickinson, USA). Antibiotic resistance was determined using the Phoenix 100 microbiological analyzer (Becton Dickinson, USA). Results A total of 3004 bacteriological tests for nonspecific microflora were performed during the analyzed period. In the structure of pathogens, E. coli comprised about half of the cases thus confirming its role as the leading uropathogen. Only piperacillin/tazobactam and nitrofurantoin provided relatively plausible antimicrobial resistance rates, for other antibacterial drugs the rates of susceptible strains progressively decreased and by 2016 dropped to 40% and lower. Conclusion Our findings cannot be extrapolated to the entire population since patients presenting for differential diagnosis receive multiple courses of treatment with various antibacterial drugs, which led to the selection of resistant strains. The findings emphasize the need for a strict selection of antibiotics for urogenital infection empirical therapy. In the absence of response, the patient should be immediately examined for tuberculosis using molecular and genetic diagnostic techniques.

Full Text

Restricted Access

About the authors

A. G Cherednichenko

Novosibirsk Tuberculosis Research Institute of Minzdrav of Russia

Dr.Med.Sci., Prof., Principal Researcher at the Department of Urology; Prof. at Department of Tuberculosis Novosibirsk, Russia

E. V Kulchavenya

Novosibirsk State Medical University of Minzdrav of Russia; NSMU

Email: urotub@yandex.ru
Head of Bacteriology Laboratory, TB Research Institute Novosibirsk, Russia

References

  1. WHO Global tuberculosis report 2015: who.int>tb/publications/ gtobal_report/en/
  2. Kulchavenya E.V. Spectrum of Urogenital Tuberculosis. J. Infect. Chemother. 2013;19(5):880-883.
  3. Kulchavenya E.V., Krasnov V.A., Mordyk A.V. Almanac of extrapulmonary tuberculosis. 2015:247 p.
  4. Kulchavenya E.V., Brizhatyuk E.V., Khomyakov V.T. Extrathoracic tuberculosis in Siberia and the Far East. Tuberkulez i bolezni legkikh. 2005;6:23-25.
  5. Kulchavenya E.V., Brizhatyuk E.V., Khomyakov V.T. New trends in the epidemic situation of extrathoracic tuberculosis in Siberia and the Far East. Tuberkulez i bolezni legkikh. 2009;10:27-31.
  6. Kulchavenya E.V., Koveshnikova E.Yu., Zhukova I.I. Clinical and epidemiological features of contemporary tuberculosis. Tuberkulez i bolezni legkikh. 2013;1:41-45.
  7. Shevchenko S.Yu., Kulchavenya E.V., Alekseeva T.V. The epidemiological situation of urogenital tuberculosis in Siberia and the Far East. Urologiia, 2016;6:65-70.
  8. Kulchavenya E.V., Breusov A.A. Efficiency ofuro-vacsom in recurrent infectious and inflammatory diseases of the genitourinary system. Urologiia. 2011;4:7-11.
  9. Kulchavenya E.V., Brizhatyuk E.V. Tuberculosis of the urinary bladder: diagnosis and treatment. Urologiia. 2006;3:61-65.
  10. Sinyakova L.A., Kosova I.V. Antimicrobial therapy of uncomplicated urinary tract infections. Consilium Medicum. 2014; 16(7) :29-33.
  11. Kulchavenya E.V., Kholtobin D.P. Reasons of delayed diagnosis of bladder tuberculosis. Urologiia, 2015;3:29-32.
  12. Perepanova T.S., Kozlov R.S., Dekhnich A.V., Palagin I.S., Shevelev A.N., Volkova E.M., Egamberdiev D.K. The choice of antimicrobial drugs for urinary tract infection. Urologiia. 2012;2:4-8.
  13. Ahangarkani F., Rajabnia R., Shahandashti E.F., Bagheri M., Ramez M. Frequency of class 1 integron in Escherichia coli strains isolated from patients with urinary tract infections in north of Iran. Mater. Sociomed. 2015;27(1):10-2. doi: 10.5455/msm.2014.27.10-12.
  14. Farshad S., Ranjbar R., Japoni A., Hosseini M., Anvarinejad M., Mohammadzadegan R. Microbial susceptibility, virulence factors, and plasmid profiles of uropathogenic Escherichia coli strains isolated from children in Jahrom, Iran. Arch. Iran. Med. 2012;15(5):312- 316. Doi: 012155/AIM.0013.
  15. Pourakbari B., Ferdosian F., Mahmoudi S., Teymuri M., Sabouni F., Heydari H., Ashtiani M.T., Mamishi S. Increase resistant rates and ESBL production between E. coli isolates causing urinary tract infection in young patients from Iran. Braz. J. Microbiol. 2012;43(2):766-769. doi: 10.1590/S1517-83822012000200041. Epub 2012 Jun 1.
  16. Shill M.C., Huda N.H., Moain F.B., Karmakar U.K. Prevalence of uropathogens in diabetic patients and their corresponding resistance pattern: results of a survey conducted at diagnostic centers in Dhaka, Bangladesh. Oman Med. J. 2010;25(4):282-285. Doi: 10.5001/ omj.2010.82.
  17. Kulchavenya E.V., Cherednichenko A.G., Neimark A.I., Shevchenko S.Yu. Incidence of nosocomial uropathogens and dynamics of their sensitivity. Urologiia, 2015;2:13-16.
  18. Qiao L.D., Chen S., Yang Y., Niu Y.J., Wang Y, Shi B.K., Yang W.M., Zhao X.K., Gao X.F., Chen M., Tian Y. Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study. BMJ Open. 2013;3(12):e004152. doi: 10.1136/bmjopen-2013-004152.
  19. Bashir S., Sarwar Y., Ali A., Mohsin M., Saeed M.A., Tariq A., Haque A. Multiple drug resistance patterns in various phylogenetic groups of uropathogenic E.coli isolated from Faisalabad region of Pakistan. Braz. J. Microbiol. 2011;42(4):1278-1283. doi: 10.1590/S1517-83822011000400005. Epub 2011 Dec 1.
  20. Mirsoleymani S.R., Salimi M., Shareghi Brojeni M., Ranjbar M., Mehtarpoor M. Bacterial pathogens and antimicrobial resistance patterns in pediatric urinary tract infections: a four-year surveillance study (2009-2012). Int. J. Pediatr. 2014;2014:126-142. doi: 10.1155/2014/126142. Epub 2014 May 19.
  21. Sedighi I., Solgi A., Amanati A., Alikhani M.Y. Choosing the correct empirical antibiotic for urinary tract infection in pediatric: Surveillance of antimicrobial susceptibility pattern of Escherichia coli by E-Test method. Iran. J. Microbiol. 2014;6(6):387-391.
  22. Çoban B., Ülkü N., Kaplan H., Topal B., Erdogan H., Baskin E. Five-year assessment of causative agents and antibiotic resistances in urinary tract infections. Turk. Pediatri Ars. 2014;49(2):124-129. doi: 10.5152/tpa.2014.1505. eCollection 2014 Jun.
  23. Malmartel A., Ghasarossian C. Epidemiology of urinary tract infections, bacterial species and resistances in primary care in France. Eur. J. Clin. Microbiol. Infect. Dis. 2016;35(3) :447-451. doi: 10.1007/s10096-015-2560-1. Epub 2016 Jan. 6.
  24. Martin D., Fougnot S., Grobost F., Thibaut-Jovelin S., Ballereau F., Gueudet T., de Mouy D., Robert J. Prevalence of extended-spectrum beta-lactamase producing Escherichia coli in community-onset urinary tract infections in France in 2013. J. Infect. 2016 ;72(2):201- 206. doi: 10.1016/j.jinf.2015.11.009. Epub 2015 Dec 15.
  25. Dreshaj Sh., Doda-Ejupi T., Tolaj I.Q., Kabashi S., Shala N., Geca Nj., Aliu A., Daka A., Basha N. Clinical role of Cefixime in community-acquired infections. Prilozi. 2011;32(2):143-155.
  26. Pistiki A., Tsaganos T., Galani I., Giamarellos-Bourboulis E.J. In Vitro Activity of Oral Cephalosporins (Cefprozil and Cefixime) Against Ciprofloxacin-Resistant Enterobacteriaceae from Community-Acquired Urinary-Tract Infections. Infect. Dis. Ther. 2015;4(4):425-32. doi: 10.1007/s40121-015-0089-3. Epub 2015 Sep 21.
  27. Rezai M.S., Salehifar E., Rafiei A., Langaee T., Rafati M., Shafahi K., Eslami G. Characterization of Multidrug Resistant Extended-Spectrum Beta-Lactamase-Producing Escherichia coli among Uropathogens of Pediatrics in North of Iran. Biomed. Res. Int. 2015;2015:309-478. doi: 10.1155/2015/309478. Epub 2015 May 3.
  28. Bingen E., Bidet P., Birgy A., Sobral E., Mariani P., Cohen R. In vitro interaction between cefixime and amoxiciliin-clavulanate against extended-spectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection. J. Clin. Microbiol. 2012;50(7):2540- 2541. doi: 10.1128/JCM.00526-12. Epub 2012 Apr 25.
  29. Madhi F., Biscardi S., Bingen E., Jaby O., Epaud R., Cohen R. Combined relay therapy with oral cefixime and clavulanate for febrile urinary tract infection caused by extended-spectrum ß-lactamase-producing Escherichia coli. Pediatr. Infect. Dis. J. 2013;32(1):96- 97. doi: 10.1097/INF.0b013e318271f369.
  30. Khosravi A.D., Abasi Montazeri E., Ghorbani A., Parhizgari N. Bacterial urinary tract infection in renal transplant recipients and their antibiotic resistance pattern: A four-year study. Iran. J. Microbiol. 2014;6(2):74-78.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies